286 related articles for article (PubMed ID: 31421110)
1. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).
Smith J; Allman D; Badri H; Miller R; Morris J; Satia I; Wood A; K Trower M
Chest; 2020 Jan; 157(1):111-118. PubMed ID: 31421110
[TBL] [Abstract][Full Text] [Related]
2. Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B; Trower M; Duggal A; Guglielmini P; Harris P; Jackson D; Lacouture ME; Ratti E; Tonini G; Wood A; Ständer S
BMJ Open; 2020 Feb; 10(2):e030114. PubMed ID: 32034016
[TBL] [Abstract][Full Text] [Related]
3. Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.
Trower MK; Fisher A; Upton N; Ratti E
Exp Dermatol; 2014 Nov; 23(11):858-60. PubMed ID: 25078633
[TBL] [Abstract][Full Text] [Related]
4. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
5. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
[TBL] [Abstract][Full Text] [Related]
6. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
Ratti E; Bettica P; Alexander R; Archer G; Carpenter D; Evoniuk G; Gomeni R; Lawson E; Lopez M; Millns H; Rabiner EA; Trist D; Trower M; Zamuner S; Krishnan R; Fava M
J Psychopharmacol; 2013 May; 27(5):424-34. PubMed ID: 23539641
[TBL] [Abstract][Full Text] [Related]
7. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial.
Khalid S; Murdoch R; Newlands A; Smart K; Kelsall A; Holt K; Dockry R; Woodcock A; Smith JA
J Allergy Clin Immunol; 2014 Jul; 134(1):56-62. PubMed ID: 24666696
[TBL] [Abstract][Full Text] [Related]
8. XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough.
Belvisi MG; Birrell MA; Wortley MA; Maher SA; Satia I; Badri H; Holt K; Round P; McGarvey L; Ford J; Smith JA
Am J Respir Crit Care Med; 2017 Nov; 196(10):1255-1263. PubMed ID: 28650204
[TBL] [Abstract][Full Text] [Related]
9. Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs.
Chapman RW; House A; Liu F; Celly C; Mei H; Hey JA
Eur J Pharmacol; 2004 Feb; 485(1-3):329-32. PubMed ID: 14757157
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.
Noronha V; Bhattacharjee A; Patil VM; Joshi A; Menon N; Shah S; Kannan S; Mukadam SA; Maske K; Ishi S; Prabhash K
Chest; 2020 Jun; 157(6):1647-1655. PubMed ID: 31958446
[TBL] [Abstract][Full Text] [Related]
11. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
[TBL] [Abstract][Full Text] [Related]
12. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
[TBL] [Abstract][Full Text] [Related]
13. Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study.
Lavorini F; Spina D; Walker MJ; Franciosi L; Page CP; Fontana GA
Pulm Pharmacol Ther; 2016 Oct; 40():91-4. PubMed ID: 27538683
[TBL] [Abstract][Full Text] [Related]
14. Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Martin Nguyen A; Bacci ED; Vernon M; Birring SS; Rosa C; Muccino D; Schelfhout J
Ther Adv Respir Dis; 2021; 15():17534666211049743. PubMed ID: 34697975
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough.
Barnabè R; Berni F; Clini V; Pirrelli M; Pisani Ceretti A; Robuschi M; Rossi M; Sestini P; Tana F; Vaghi A
Monaldi Arch Chest Dis; 1995 Apr; 50(2):93-7. PubMed ID: 7613554
[TBL] [Abstract][Full Text] [Related]
16. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Neurokinin-1 Receptor Antagonism as a Novel Treatment for Chronic Bronchitis in Dogs.
Grobman M; Reinero C
J Vet Intern Med; 2016 May; 30(3):847-52. PubMed ID: 26995558
[TBL] [Abstract][Full Text] [Related]
18. [Rengalin, a New Efficacious and Safe Antitussive Agent. Results of a Randomized, Comparative, Multicenter Clinical Trial in Patients with Acute Respiratory Tract Infections].
Akopov AL; Aleksandrova EB; Il'kovich MM; Petrov DV; Trofimov VI
Antibiot Khimioter; 2015; 60(1-2):19-26. PubMed ID: 26168681
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of montelukast in the treatment of cough variant asthma.
Spector SL; Tan RA
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):232-6. PubMed ID: 15478381
[TBL] [Abstract][Full Text] [Related]
20. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease.
Smith J; Owen E; Earis J; Woodcock A
J Allergy Clin Immunol; 2006 Apr; 117(4):831-5. PubMed ID: 16630941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
